BioCentury | Sep 15, 2020
Emerging Company Profile

Attralus debuts with $25M series A to tackle systemic amyloidosis

Attralus debuted on Monday with a $25 million series A round from venBio Partners, a pan-amyloid imaging agent and a pair of candidates that can be developed for multiple types of systemic amyloidosis.  The company’s...
BioCentury | Apr 13, 2017
Distillery Therapeutics


...ovarian cancers and preclinical testing for multiple other cancers. Amrita Therapeutics Ltd. has AT-01C and AT-01D...
BioCentury | Mar 23, 2017
Clinical News

APX005M: Ph I/II started

Apexigen began an open-label, U.S. Phase I/II trial to evaluate intratumoral APX005M given every 3 weeks for up to 4 doses plus IV Keytruda pembrolizumab in about 41 patients. The Phase I portion will evaluate...
BioCentury | May 9, 2016
Product Development

Community organizers

With new papers published by the day and a flurry of big-dollar deals and financings, it's hard to separate the signal from the noise in the microbiome space. The space has become so hot that...
BioCentury | Nov 21, 2011
Product Development

Combo conundrums

The development of combinations of investigational agents for cancer gained steam in 2009 with a deal between Merck & Co. Inc. and AstraZeneca plc . At least six more companies have joined forces since and many...
BioCentury | Jun 8, 2009
Clinical News

IV TRC105: Phase I data

Data from 19 patients in a dose-escalation Phase I trial showed that 0.01-1.0 mg/kg IV TRC105 resulted in 5 cases of stable disease. The compound was well tolerated, with 1 case of grade 4 gastric...
BioCentury | Dec 4, 2006
Clinical News

CF101: Phase IIa data

In a double-blind Phase IIa trial in 74 RA patients, oral CF101 reduced disease activity. Maximal responses were seen at a twice-daily dose of 1 mg of CF101, with lower responses at 0.1 and 4...
BioCentury | Dec 9, 2002
Clinical News

rhuIL-4 autoimmune/inflammation data

In an open-label, dose-escalating European study in 20 patients with severe psoriasis, all patients showed decreased clinical scores within 6 weeks. In all, 19 patients had a ?50% PASI reduction and 15 had a ?68%...
BioCentury | May 13, 2002

Ebb & Flow

A little more than two years after its hyped-up creation, a piece of the Franco-American venture ValiGen N.V. filed for bankruptcy protection last week, and the financial outlook for its other ventures remain uncertain. ValiGen...
BioCentury | May 29, 2001
Clinical News

Neurocrine preclinical data

NBIX reported that CRF1 receptor agonists restored normal function in a rat model of stress-induced gastrointestinal disturbances that occur in IBS. A single oral dose of the CRF1 receptor antagonist increased colonic transit 12-fold. In...
Items per page:
1 - 10 of 12